GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hisamitsu Pharmaceutical Co Inc (TSE:4530) » Definitions » Intrinsic Value: Projected FCF

Hisamitsu Pharmaceutical Co (TSE:4530) Intrinsic Value: Projected FCF : 円4,409.48 (As of May. 12, 2024)


View and export this data going back to 1962. Start your Free Trial

What is Hisamitsu Pharmaceutical Co Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-12), Hisamitsu Pharmaceutical Co's Intrinsic Value: Projected FCF is 円4,409.48. The stock price of Hisamitsu Pharmaceutical Co is 円3823.00. Therefore, Hisamitsu Pharmaceutical Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.9.

The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Intrinsic Value: Projected FCF or its related term are showing as below:

TSE:4530' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.81   Med: 1.05   Max: 1.59
Current: 0.87

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Hisamitsu Pharmaceutical Co was 1.59. The lowest was 0.81. And the median was 1.05.

TSE:4530's Price-to-Projected-FCF is ranked better than
78.6% of 598 companies
in the Drug Manufacturers industry
Industry Median: 1.59 vs TSE:4530: 0.87

Hisamitsu Pharmaceutical Co Intrinsic Value: Projected FCF Historical Data

The historical data trend for Hisamitsu Pharmaceutical Co's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hisamitsu Pharmaceutical Co Intrinsic Value: Projected FCF Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,994.08 4,557.53 4,538.55 4,318.54 4,409.48

Hisamitsu Pharmaceutical Co Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,318.54 - - - 4,409.48

Competitive Comparison of Hisamitsu Pharmaceutical Co's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hisamitsu Pharmaceutical Co's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's Price-to-Projected-FCF falls into.



Hisamitsu Pharmaceutical Co Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Hisamitsu Pharmaceutical Co's Free Cash Flow(6 year avg) = 円12,824.14.

Hisamitsu Pharmaceutical Co's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Feb24)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*12824.142857143+264871*0.8)/75.743
=4,409.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hisamitsu Pharmaceutical Co  (TSE:4530) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Hisamitsu Pharmaceutical Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=3823.00/4409.4787494142
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hisamitsu Pharmaceutical Co Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Hisamitsu Pharmaceutical Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hisamitsu Pharmaceutical Co (TSE:4530) Business Description

Traded in Other Exchanges
Address
408 Tashiro Daikan-machi, Tosu, Saga, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.

Hisamitsu Pharmaceutical Co (TSE:4530) Headlines

No Headlines